Who is sponsoring NCT05793281?

NCT05793281 is sponsored by Bayer.

What drugs are being tested in NCT05793281?

Interventions in NCT05793281: No Drug.

What condition does NCT05793281 study?

NCT05793281 studies Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion.

Is NCT05793281 still recruiting?

NCT05793281 is currently completed. Last updated 25 October 2023.

Last reviewed 2023-10-25 · How we verify

NCT05793281

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Completed Last updated 25 October 2023

What this trial tests

trial testing No Drug in Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion in 46,621 participants. Completed in 28 September 2023.

Timeline

10 March 2023

Primary endpoint
28 September 2023

28 September 2023

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	46,621
Start date	10 March 2023
Primary completion	28 September 2023
Estimated completion	28 September 2023
Sites	1 location across Japan

Drugs / interventions tested

No Drug — full drug profile →

Conditions studied

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion — all drugs for Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational studies, only observations are made without specified advice or interventions. Advanced or recurrent solid tumor harboring an NTRK gene fusion is a rare type of solid cancer caused by specific changes in the genes called NTRK gene fusion, and which has spread to nearby tissues and/or lymph nodes or has returned. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive. The main purpose of this study is to learn more about NTRK gene fusion in people in Japan. To do this, researchers will collect information on the number or percentage of Japanese people with NTRK gene fusion in any solid tumor. The data will come from the national database called C-CAT. They will cover the period from June 2019 until January 2023. Besides this data collection, no further tests or examinations are planned, and no visits are required in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan.
Nakata E, Osone T, Ogawa T, Taguchi T, et al · · 2024 · cited 10× · PMID 38925616 · DOI 10.1002/cam4.7351

Verify or expand the search:

Other trials of No Drug

Trials testing the same drug.

NCT07516015 — Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC · not yet recruiting
NCT06812117 — A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuro · active not recruiting
NCT06546202 — Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China · completed

Other recruiting trials for Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Currently open trials in the same condition.

NCT04945330 — NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05793281 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 25 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05793281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing